Nothing Special   »   [go: up one dir, main page]

WO2002055064A3 - Mucopolysaccharidosis therapies - Google Patents

Mucopolysaccharidosis therapies Download PDF

Info

Publication number
WO2002055064A3
WO2002055064A3 PCT/US2002/000813 US0200813W WO02055064A3 WO 2002055064 A3 WO2002055064 A3 WO 2002055064A3 US 0200813 W US0200813 W US 0200813W WO 02055064 A3 WO02055064 A3 WO 02055064A3
Authority
WO
WIPO (PCT)
Prior art keywords
mucopolysaccharidosis
therapies
inhibitors
diseases
treatment
Prior art date
Application number
PCT/US2002/000813
Other languages
French (fr)
Other versions
WO2002055064A2 (en
Inventor
Steven Walkley
Original Assignee
Oxford Glycosciences Uk Ltd
Steven Walkley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0100889.5A external-priority patent/GB0100889D0/en
Application filed by Oxford Glycosciences Uk Ltd, Steven Walkley filed Critical Oxford Glycosciences Uk Ltd
Priority to AU2002241853A priority Critical patent/AU2002241853A1/en
Publication of WO2002055064A2 publication Critical patent/WO2002055064A2/en
Publication of WO2002055064A3 publication Critical patent/WO2002055064A3/en
Priority to US10/619,378 priority patent/US20050032841A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/45—Transferases (2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The use of inhibitors of glycosylceramide synthesis in the treatment of mucopolysaccharidosis diseases.
PCT/US2002/000813 1999-04-20 2002-01-11 Mucopolysaccharidosis therapies WO2002055064A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002241853A AU2002241853A1 (en) 2001-01-12 2002-01-11 Mucopolysaccharidosis therapies
US10/619,378 US20050032841A1 (en) 1999-04-20 2003-07-14 Therapeutic compositions and methods of treating glycolipid storage related disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0100889.5A GB0100889D0 (en) 2001-01-12 2001-01-12 Compounds
GB0100889.5 2001-01-12
US34723302P 2002-01-10 2002-01-10
US60/347,233 2002-01-10

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/619,378 Continuation US20050032841A1 (en) 1999-04-20 2003-07-14 Therapeutic compositions and methods of treating glycolipid storage related disorders

Publications (2)

Publication Number Publication Date
WO2002055064A2 WO2002055064A2 (en) 2002-07-18
WO2002055064A3 true WO2002055064A3 (en) 2002-09-26

Family

ID=26245554

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/000813 WO2002055064A2 (en) 1999-04-20 2002-01-11 Mucopolysaccharidosis therapies

Country Status (2)

Country Link
AU (1) AU2002241853A1 (en)
WO (1) WO2002055064A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT202200007808A1 (en) 2022-04-20 2023-10-20 Luigi Michele Pavone THERAPEUTIC COMPOSITIONS FOR DISEASES CAUSED BY ACCUMULATION OF EPARAN SULFATE

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062779A1 (en) * 1999-04-20 2000-10-26 Oxford Glycosciences (Uk) Limited Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy
WO2001097829A2 (en) * 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062779A1 (en) * 1999-04-20 2000-10-26 Oxford Glycosciences (Uk) Limited Combination of glucosylceramide synthesis inhibitors and glycolipid degrading enzyme in therapy
WO2001097829A2 (en) * 2000-06-19 2001-12-27 Genzyme Corporation Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
PLATT F M ET AL: "N-BUTYLDEOXYNOJIRIMYCIN IS A NOVEL INHIBITOR OF GLYCOLIPID BIOSYNTHESIS", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 269, no. 11, 18 March 1994 (1994-03-18), pages 8362 - 8365, XP000615445, ISSN: 0021-9258 *
PLATT F M ET AL: "NEW THERAPEUTIC PROSPECTS FOR THE GLYCOSPHINGOLIPID LYSOSOMAL STORAGE DISEASES", BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 56, no. 4, 1998, pages 421 - 430, XP000886851, ISSN: 0006-2952 *

Also Published As

Publication number Publication date
WO2002055064A2 (en) 2002-07-18
AU2002241853A1 (en) 2002-07-24

Similar Documents

Publication Publication Date Title
AU2001259758A1 (en) Interleukin-1 inhibitors in the treatment of diseases
WO2004006858A3 (en) Compounds, compositions, and methods employing same
AU2003286567A1 (en) Methods for the treatment of skin disorders
AU2002339157A1 (en) Inhibitors of the notch signalling pathway for use in the treatment of cancer
AU2002352443A1 (en) Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2006015263A3 (en) Lonidamine analogs
WO2004089296A3 (en) Improved inhibitors for the soluble epoxide hydrolase
ZA200203123B (en) Therapeutic use of selective PDE10 inhibitors.
MXPA04003668A (en) Type 4 phosphodiesterase inhibitors and uses thereof.
AU2003261251A1 (en) Methods of delivering therapeutic agents
AU2003300791A1 (en) Combination therapy for the treatment of pain
ZA200108413B (en) Use of glycosyceramide synthesis inhibitors in therapy.
AU2002334870B8 (en) Combinations for the treatment of immunoinflammatory disorders
WO2003088748A8 (en) Use of heme oxygenase-1 and products of heme degradation
AU2002248269A1 (en) Use of p38 inhibitors for the treatment of inflammation-enhanced cough
AU2001288101A1 (en) Ultrasonic beauty treatment probe
MXPA03003741A (en) Methods and compositions for the treatment of diseases of the eye.
AU2001228703A1 (en) Use of cox-2 inhibitors for the treatment of constipation
WO2002039997A3 (en) Ace-2 modulating compounds and use thereof
MXPA03007653A (en) Use of lp82 to treat hematopoietic disorders.
WO2002060483A3 (en) Perylenequinones for use as photosensitizers and sonosensitizers
AU2003259246A1 (en) Methods for the use of neurotoxin in the treatment of urologic disorders

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP